Physician profile
Maher Loutfi
NPI 1336365162
$15,312.53
in general payments reported to CMS, 2019-2025
50 companies · $3,304 in 2025
The $3,304 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $1,017 · 2021: $2,384 · 2022: $2,804 · 2023: $2,533 · 2024: $2,828 · 2025: $3,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,322 · Education: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,322.44 |
| Education | $343.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,069.37 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Abbvie INC. | $1,671.22 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,454.65 | 2019-2025 | |
| Lilly USA, LLC | $1,436.78 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Pfizer INC. | $1,024.83 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $889.69 | 2020-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Lundbeck LLC | $781.61 | 2020-2025 | Vyepti, Rexulti |
| Genentech USA, INC. | $609.88 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Celgene Corporation | $527.32 | 2020-2025 | Zeposia |
| Eisai INC. | $413.12 | 2022-2025 | |
| Neurelis, INC. | $360.76 | 2021-2025 | Valtoco |
| Biogen, INC. | $349.34 | 2020-2025 | Vumerity, Tysabri, Leqembi |
| Biohaven Pharmaceuticals, INC. | $336.65 | 2020-2021 | |
| Ucb, INC. | $318.33 | 2019-2024 | Briviact, Rystiggo |
| Alexion Pharmaceuticals, INC. | $274.35 | 2021-2023 | Soliris |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maher Loutfi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.